Fox Business - The Power to Prosper
Search Site

Regeneron Pharmaceuticals

Biotechs Still Hold Promise in 2014 and Beyond

As a group, biotech companies were among the best performers in what was a stellar year for U.S. stocks: The group was up 66%, outpacing the broader market by a staggering 3,600 basis points. Behind that marquee performance, it was imperative to look at names that had the best therapies for the most onerous diseases. Perhaps more than any other group, biotechs rise and fall on headlines, so for every whisper of FDA approval for new drugs, there's the specter of rejection after years and billions of dollars are spent in development.  For every rumored richly-valued takeout by a large-cap pharmaceutical looking to beef up its product pipeline, there's the chance that clinical trials can fail early and spectacularly before therapies even make it to regulatory hearings. That's why you see biotechs move double and even triple digit percentages in a day on good news, or plummet by as much as 50% or more on bad.  This year undoubtedly will be a stock picker's market, and especially so in biot...

Read More

  1. Regeneron to Join S&P 500 After MetroPCS Merger with T-Mobile

    Standard & Poor's said it will add biopharmaceutical company Regeneron Pharmaceuticals Inc. (REGN) to the S&P 500 index, replacing MetroPCs Communications Inc. (PCS)...

  2. Sanofi and Regeneron See Positive Results From Atopic Dermatitis Drug Studies

    Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN) said results from two studies of its treatment for atopic dermatitis were positive.The drug companies said poo...

  3. EUROPE MARKETS: Europe Stocks Rally As German ZEW Index Posts Rise

    European stock markets posted broad-based gains on Tuesday, boosted by stronger-than-expected German investor-sentiment data, while shares of Danone SA were among ma...

  4. EUROPE MARKETS: Europe Stocks Rise After German ZEW Report

    European stock markets posted broad-based gains on Tuesday, boosted by stronger-than-expected German economic-sentiment data, with shares of Danone SA among major ad...

  5. Bayer, Regeneron to Launch New Phase III Study for VEGF Trap-Eye

    Bayer HealthCare and Regeneron Pharmaceuticals, Inc. said Tuesday they initiated a new Phase III trial of VEGF Trap-Eye in the treatment of Diabetic Macular Edema in...

  6. ADR Shares Close Mixed As Novo Nordisk Drops On FDA News

    International companies trading in New York closed mixed Monday, as Novo Nordisk AS (NVO, NOVO-B.KO) led European stocks lower, while most Asian markets were closed ...

  7. Sanofi boosting stake in Regeneron

    French drugmaker Sanofi SA is buying more shares in U.S. biotech company Regeneron Pharmaceuticals Inc , its partner in the development of potential blockbuster trea...

  8. Regeneron says Sanofi to boost stake in its shares

    Regeneron Pharmaceuticals Inc said its longtime drug-development partner Sanofi SA aims to boost its stake in the U.S. biotechnology company through open market purc...

  9. EUROPE MARKETS: Novo Nordisk Leads Europe Lower After FDA News

    Novo Nordisk AS on Monday knocked the air out of Europe's benchmark stock index after a setback in the U.S., while the region's bourses saw mixed trade as a meeting ...

  10. Regeneron says Sanofi plans to buy shares

    Regeneron Pharmaceuticals Inc on Monday said it has received notice that Sanofi SA intends to acquire Regeneron's common stock through open market purchases and dire...

  11. Regeneron Shares Jump On Sanofi Share Buy Plan

    Shares of Regeneron Pharmaceuticals Inc. were up 8% to $179 in early trading Monday after French drug maker Sanofi SA announced its intention to purchase a piece of ...

  12. Regeneron : Sanofi Plans to Increase Stake to Over $500 Million of Stock

    Regeneron Pharmaceuticals Inc. (REGN) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and ...

  1. What to Expect From Tesla Shares After Joining QQQ (TSLA)

    Electric car maker Tesla (NASDAQ:TSLA) is no stranger to fanfare.The company and its high-flying shares got a little bit more of that on Monday evening when NASDAQ O...

  2. Market Wrap for Thursday, June 6: Stocks Reverse Mid-Day; Rally to Close at Session Highs

    The U.S. stock market surged on Thursday after an afternoon rally lifted the major averages out of negative territory.Stocks closed near their best levels of the ses...

  3. Regeneron -Sanofi Asthma Drug Shows Promising Early Results

    An experimental drug being developed by Regeneron Pharmaceuticals Inc. (REGN) and Sanofi SA (SNY) showed promising results during a small, mid-stage clinical trial i...

  4. Market Wrap for Friday, May 3: Stocks Jump on Strong Jobs Data

    The U.S. stock market jumped on Friday to end the trading week. The catalyst for the move higher was a strong jobs report, which briefly sent the Dow Jones Industria...

  5. Allergan Reports Drug Development Delay, Lower Profits

    Allergan Inc. (AGN) said it won't advance two of its key pipeline drugs into late stage trials needed for regulatory approval as quickly as it had hoped, sending the...

  6. Market Wrap for Wednesday, May 1: Stocks Fall as Employment Data Weakens in April

    The U.S. stock market was hit hard on Wednesday as investors reacted to a report which showed slowing employment conditions for the month of April.The losses were al...

  7. Regeneron Pharmaceuticals Co-Founder Receives $81.55 Million Compensation

    Regeneron Pharmaceuticals Inc.'s (REGN) stock price tripled last year, and the compensation of co-founder and Chief Executive Leonard Schleifer nearly did, too.Mr. S...

‹ Prev123Next ›
Freebase CC-BY
Source: Regeneron Pharmaceuticals on Freebase, licensed under CC-BY
Other content from Wikipedia, licensed under the GFDL